Mary Caffrey

The cancer care community descends on Chicago this weekend for the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO). This year’s theme, “Partnering With Patients: The Cornerstone of Cancer Care and Research,” highlights how recent advances make interactions between clinicians and patients more important than ever, as shared decision-making must be the foundation of the care journey.

Andrew Evens, DO, MBA, MSc, associate director for clinical services at Rutgers Cancer Institute, discussed the ways in which SWOG S1826 trial results will build on current knowledge of Hodgkin lymphoma treatment.

Coverage from the Greater Philadelphia Business Coalition on Health (GPBCH) daylong Oncology Management Summit, held April 4, 2023.

Coverage from the Greater Philadelphia Business Coalition on Health (GPBCH) daylong Oncology Management Summit, held April 4, 2023.

Approval for the T-cell–engaging bispecific antibody came today from the FDA.

A panel of top practice administrators, moderated by Danielle Geiger, APRN-NP, of Nebraska Cancer Specialists, explored ways for practices to improve the bottom line at the Quality Cancer Care Alliance (QCCA) spring conference, held April 19-21, 2023.

The task force was motivated by a gap between in breast cancer deaths between Black and White women.

For Brain Cancer Awareness Month, AJMC shares an interview with Day One Biopharmaceuticals CEO Jeremy Bender, PhD, MBA. Bender discussed the company's lead agent, tovorafenib, which has shown promise in treatment of pediatric low-grade glioma.

An expert panel at the recent meeting of the Quality Cancer Care Alliance discussed the Enhancing Oncology Model (EOM), which is set to begin on July 1, 2023.

Daiichi Sankyo announced that the new deadline for review of the application is July 24, 2023.

Under the transaction, TPG, an asset management firm, will acquire a majority interest in OneOncology and AmerisourceBergen will have a minority interest; OneOncology physician leaders and practices will retain minority interests as well.

The Community Oncology Alliance celebrated its 20th year at the Community Oncology Conference held March 23-24, 2023, in Kissimmee, Florida.

Coverage from the American College of Cardiology Scientific Session Together With World Congress of Cardiology, held March 4-6, 2023, in New Orleans, Louisiana.

Oncologists express concerns about the replacement for the Oncology Care Model; the EOM is set to start July 1, 2023.

This combination is among the many cancer vaccine collaborations being pursued.

The April 2 plenary session at the National Comprehensive Cancer Network (NCCN) 2023 Annual Conference, entitled, “Sleep Disorders, Fatigue, and Cognitive Function in Cancer Survivors" reviewed guidelines for handling symptoms that are increasingly common as the survivorship ranks grow.

An April 1 session at the 2023 National Comprehensive Cancer Network (NCCN) on updates in CLL/SLL featured results on the ALPINE study, which led to the January 2023 approval of zanubrutinib in the frontline setting.

As much as immuno-oncology has been a leap forward, the ability to address immune-related adverse events is critical to making these therapies available in settings beyond academic centers; thus, the National Comprehensive Cancer Network offers clinical guidelines for management of toxicities.

Natalie S. Callander, MD, director of the University of Wisconsin Carbone Cancer Center Myeloma Clinical Program, reviewed the treatment landscape at the National Comprehensive Cancer Network (NCCN) 2023 Annual Conference.

Results for this study, involving use of this CDK4/6 inhibitor with endocrine therapy, will be presented at an upcoming scientific meeting and submitted to regulators.

Based on promising results, the biotech IMV has moved into phase 2b trials with a cancer vaccine composed of survivin epitopes that uses the company’s proprietary delivery system to elicit persistent immune responses.

A panel at the Community Oncology Alliance (COA) 2023 Community Oncology Conference highlights the evolution of taking on risk, developing stratification models, and collaborating to learn from fellow providers.

Capitol Hill experts taking part in the Community Oncology Alliance's (COA) Community Oncology Conference said Friday that bipartisan awareness of pharmacy benefit manager (PBM) practices has reached a point that they believe Congress may finally act, if only to require greater transparency.

A chief concern among those considering the upcoming alternative payment model in oncology, the Enhancing Oncology Model (EOM): Practices will have to take on downside risk immediately.

The Community Oncology Alliance (COA) retains the spirit of an upstart advocacy group, while working to look ahead at innovative technologies, care delivery trends, and other events that threaten independent practices, said oncology leaders while attending their annual meeting this week.

Topics to be addressed at the annual conference, which will bring more than 1900 attendees to Kissimmee, Florida, include the Enhancing Oncology Model, efforts to regulate pharmacy benefit managers, and 340B reform.

The findings, published in the Journal of the National Comprehensive Cancer Network, add to the evidence that the shift to precision medicine is built on data that have not included sufficient numbers of patients of color.

Ajai Chari, MD, professor of medicine and director of clinical research in the Multiple Myeloma Program at Mount Sinai in New York, discusses a post-hoc analysis of data from the phase 2 GRIFFIN trial.

Speaking at the 72nd American College of Cardiology Scientific Session in New Orleans on Sunday, Clyde W. Yancy, MD, MSc, the vice dean for diversity and inclusion at the Feinberg School of Medicine at Northwestern University, challenged the audience to rethink what success looks like in health care.

Results for the STELLAR trial, presented at the 72nd American College of Cardiology (ACC) Scientific Session Together With the World Congress of Cardiology, hit nearly every mark: patients taking sotatercept improved their performance on a 6-minute walk test by 40.8 meters, which was the primary end point, and achieved 8 of 9 secondary end points.